Hematologists near Elmhurst, NY

Biography: Brandon Swed, MD is an Assistant Professor of Clinical Medicine in the Division of Hematology and Medical Oncology at Weill Cornell Medicine and an Attending Physician at NewYork-Presbyterian Brooklyn Methodist Hospital. His clinical interest is in gastrointestinal (GI) malignancies. His research is focused on novel therapeutics and drug development for pancreatic cancer. Dr. Swed received his B.S. in Neuroscience and Chemistry from the University of Miami. He earned his medical degree from the Lewis Katz School of Medicine at Temple University, where he was the recipient of the Weinberger Award for distinction in Hematology and Medical Oncology and was inducted into the Gold Humanism Honor Society. He completed his internship and residency in Internal Medicine at the Hospital of the University of Pennsylvania, where he led several quality improvement initiatives as part of the Healthcare Leadership in Quality program. He continued his medical training at New York-Presbyterian/Weill Cornell Medicine, where he completed his clinical fellowship in Hematology and Medical Oncology, having served as chief fellow during his final year. Dr. Swed cares for patients with a broad array of hematologic and oncologic diseases, with a particular focus on treating patients with gastrointestinal (GI) cancers. He has also been involved in several translational and clinical research projects focused on novel therapies for pancreatic cancer and was selected to participate in the 2021 AACR-ASCO Methods in Clinical Cancer Research Workshop to further develop this work.

Biography: Dr. Shambavi Richard, MD is a Hematology Specialist who practices in New York, NY. She is 61 years old and has been practicing for 37 years. Dr. Shambavi Richard, MD is affiliated with Mount Sinai Morningside, Mount Sinai Hospital and Mount Sinai Queens.

Biography: Dr. Deborah Doroshow, MD is a Hematology Specialist who practices in New York, NY. She is 42 years old. Dr. Deborah Doroshow, MD is affiliated with Mount Sinai Morningside and Mount Sinai Hospital.

Biography: Dr. Thomas Marron, MD is a Hematology Specialist who practices in New York, NY. He is 44 years old and has been practicing for 13 years. Dr. Thomas Marron, MD is affiliated with Mount Sinai Hospital and Mount Sinai Morningside.

Biography: Dr. John Levine, MD is an Oncology Specialist who practices in New York, NY. He is 62 years old and has been practicing for 36 years. Dr. John Levine, MD is affiliated with Mount Sinai Hospital.

Biography: Dr. Bridget Marcellino, MD is a Hematology Specialist who practices in New York, NY. She is 42 years old and has been practicing for 11 years. Dr. Bridget Marcellino, MD is affiliated with Mount Sinai Hospital and Mount Sinai Morningside.

Biography: Dr. Aarti Bhardwaj, MD is a Hematology Specialist who practices in New York, NY. She is 43 years old and has been practicing for 17 years. Dr. Aarti Bhardwaj, MD is affiliated with Mount Sinai Hospital.

Biography: Dr. Samir Parekh, MB BS is a Hematology Specialist who practices in New York, NY. He is 50 years old and has been practicing for 26 years. Dr. Samir Parekh, MB BS is affiliated with Mount Sinai Hospital.

Biography: Dr. Erin Mulvey is an Assistant Professor of Medicine in the Division of Hematology and Medical Oncology at Weill Cornell Medicine. She is also an assistant attending physician at NewYork-Presbyterian Queens, She completed her undergraduate education at Boston University where she earned a degree in Biochemistry and Molecular Biology. She received her medical degree from New York Medical College. Dr. Mulvey completed both her Residency in Internal Medicine and her Fellowship in Hematology/Oncology at NewYork-Presbyterian Hospital and Weill Cornell Medical College.

Biography: Nausheen Hakim, DO, is a hematologist and oncologist at NewYork-Presbyterian Medical Group Queens, affiliated with NewYork-Presbyterian Queens Hospital. She is an assistant professor of clinical medicine at Weill Cornell Medicine. Dr. Hakim has a special interest in the area of genitourinary cancers. Active in research, Dr. Hakim has published in several medical journals, as well as delivered presentations at the American Society of Clinical Oncology and the World Lung Conference. After obtaining her bachelor of arts in anthropology while pursuing the pre-medicine track, she volunteered for one year with AmeriCorps at the nonprofit South Asian Youth Action (SAYA). She graduated from New York College of Osteopathic Medicine and completed her internal medicine residency at Drexel University/Hahnemann Hospital in Philadelphia. She served her hematology and medical oncology fellowship at the Northwell Health Cancer Institute. Dr. Hakim remains dedicated to the world of nonprofit by participating on the advisory board of Unite for Health. With a commitment to working in global health, she strives to better understand palliative care barriers in not only communities abroad, but in our own communities here in Queens.

Biography: Caitlin Gribbin, MD, is an Instructor in Medicine within the Division of Hematology and Oncology at Weill Cornell Medical Center. After earning her B.A. from Cornell University, Dr. Gribbin received her Medical Degree as well as Masters in Science from Weill Cornell Medical College. She completed her Internship and Residency as well as subsequent Fellowship training in Hematology and Oncology within the Medical Research Track at Weill Cornell Medicine/NewYork-Presbyterian Hospital. As a faculty member at Weill Cornell, Dr. Gribbin specializes in treating patients with lymphoma using cellular therapies, including chimeric antigen receptor (CAR) T cell therapy. She is simultaneously focused on leading clinical and translational research studies aimed at improving lymphoma treatments by bringing novel scientific discoveries to patients. Dr. Gribbin has co-authored numerous publications and presentations at national and international meetings and has received several research grants, including the American Society of Clinical Oncology (ASCO) Young Investigator Award, the Lymphoma Research Foundation (LRF) Scientific Research Mentoring Program Award, and the Burroughs Wellcome Fund Award.

Biography: Dr. Chris Hackett received his BS in Biological Sciences from Stanford University in 2000. After doing biomedical research in industry and academia, he then pursued graduate studies in cancer genomics at the University of California, San Francisco, where he earned his PhD in 2010. Seeking to become a physician-scientist, he then earned his medical degree (MD) from the University of Minnesota in 2014. He then completed his Internal Medicine Residency at NewYork-Presbyterian/Weill Cornell Medical Center, followed by a fellowship in Medical Oncology at Memorial Sloan Kettering Cancer Center (MSK), where he focused on solid tumor oncology in the clinic and carried out laboratory research to design T cell therapies for cancer. Following fellowship, Dr. Hackett was an attending on the Cellular Therapeutics Service at MSK, where he focused on treating patients with CAR T cells, Tumor Infiltrating Lymphocytes (TIL) and other cell therapies. In 2023, he joined the Bone Marrow Transplant Service at Weill Cornell Medicine and NewYork-Presbyterian Hospital, where he continues to both treat patients with cellular therapies and conduct research to develop new cell therapies for solid tumors.

Care Philosophy: I am a medical oncologist specializing in the treatment of patients with genitourinary malignancies (including prostate, bladder, testes, and kidney cancers). My clinical and translational research focuses on development of new treatment strategies for patients. In particular, I am studying the genetics of prostate cancer, and I am involved in developing personalized treatment approaches for patients based on their cancer's specific molecular alterations. My clinical practice and research rely on close collaborations with clinicians, scientists, and physician scientists from multiple disciplines including pathology, urology, radiology, radiation oncology, computational biology, pharmacology, and medical oncology. Most recently, we have expanded these clinical and research efforts across cancer types as part of our new Institute for Precision Medicine

Biography: Ghaith Abu-Zeinah, MD, is an Assistant Professor in Medicine at Weill Cornell Medical College and an Assistant Attending Physician at the NewYork-Presbyterian Hospital. Dr. Abu-Zeinah earned his M.D. with academic distinction from the Weill Cornell Medical College in Qatar in 2013. He completed his residency training in Internal Medicine (2016) and fellowship training in Hematology/Oncology (2019) at the NewYork-Presbyterian Hospital/Weill Cornell Medicine in New York City.Dr. Abu-Zeinah is a Hematologist and Oncologist with a specialty practice in Myeloproliferative Neoplasms (MPN). His laboratory and clinical research is focused on identifying and developing therapies that target the malignant stem cells in patients with MPN. He received several awards for his work and presented at national conferences including the International Congress on Myeloproliferative Neoplasms and the American Society of Hematology. He has joined the Richard T Silver MPN Center as a physician-scientist both treating patients and conducting research.

Biography: Dr. Justin Kaner graduated with a B.S. in Biology from Syracuse University in 2009 where his initial interest in hematologic malignancies developed. He received his M.D. from New York Medical College in 2013 before completing his Internal Medicine Residency at Albert Einstein College of Medicine/Montefiore Medical Center. During residency Dr. Kaner pursued his interest in hematologic malignancies by undertaking several research projects mainly focused on myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) which led to several publications in peer reviewed journals, including Leukemia and Lymphoma and Oncotarget, as well as numerous abstracts presented at the American Society of Clinical Oncology (ASCO) and American Society of Hematology (ASH) Annual Meetings. Additionally, Dr. Kaner served as Chief Resident after his residency at Montefiore Medical Center.Throughout his Hematology/Oncology fellowship at Weill Cornell Medicine and NewYork-Presbyterian Hospital, Dr. Kaner worked in the laboratory of Dr. Monica Guzman and with clinical mentorship from Dr. Ellen Ritchie and Dr. Gail Roboz of the Weill Cornell Leukemia Program. During this time, he studied the activity of a novel therapeutic, PU-H71, in PTPN11 mutated AML as well as the prognostic impact of PTPN11 mutations in AML. During his fellowship training Dr. Kaner also developed a particular interest in early phase clinical trials and novel therapeutics for the treatment of Relapsed/Refractory AML. Dr. Kaner accepted an opportunity to remain at Weill Cornell, joining the Leukemia Program to focus on caring for hospitalized patients with various acute and chronic leukemias, MDS and myeloproliferative neoplasms (MPNs).

Biography: Samuel Yamshon, M.D. is an Assistant Professor of Medicine at Weill Cornell Medicine/New York Presbyterian Hospital. Dr. Yamshon cares for patients with blood cancers with a specific focus on lymphoma and improving outcomes for patients using innovative treatments like cellular immunotherapies including CAR T-cell therapy.Dr. Yamshon received his B.A. from Columbia University and completed his medical training at the University of California, Davis. He returned to New York to train in Internal Medicine at Weill Cornell Medicine, where he also completed his fellowship in Hematology and Oncology. At Weill Cornell Medicine, he specializes in treating patients with lymphoma using cellular therapies including bone marrow transplantation and CAR T cell therapy, and is involved in clinical research dedicated to improving outcomes for patients with lymphoma. He has been involved in lymphoma research for over a decade, co-authoring numerous publications and several presentations at national meetings. Dr. Yamshon is also an Editorial Fellow for the journal Leukemia & Lymphoma. He has received multiple research grants including the American Society of Clinical Oncology (ASCO) Young Investigator Award and the Lymphoma Research Foundation (LRF) Scientific Research Mentoring Program.

Biography: Maria is a Pediatric Hemophilia Nurse Practitioner at Weill Cornell Medicine, bringing over nine years of nursing experience to her role. She began her journey at Quinnipiac University, where she graduated with honors in nursing, and then joined Memorial Sloan Kettering Cancer Center, caring for oncology patients. While working full-time as an RN, Maria pursued her master's degree at Pace University, earning her Family Nurse Practitioner (FNP) certification. Her extensive experience and dedication make her an asset in the field of pediatric hemophilia care.

Biography: Ms. Kleinert received her Doctor of Nursing Practice (DNP) degree at Case Western Reserve University and her Pediatric Nurse Practitioner (PNP) degree at New York University, where she also received her MA degree in Adult Primary Care. She has also completed her Master of Public Health degree (MPH) at Columbia University.

Biography: Hanna Rosen, NP is a Radiation Oncology Specialist who practices in New York, NY. Hanna Rosen, NP is affiliated with Weill Cornell Medical Center.

Care Philosophy: Alexander J. Chou, MD, is a pediatric oncologist specializing in the treatment of pediatric sarcomas, rare cancers of the bone and soft tissues at Children's Hospital at Montefiore. Dr. Chou, along with his colleagues, provides state-of-the-art therapies to patients with sarcomas in a comprehensive and multidisciplinary setting. Dr. Chou is the Clinical Director of the Pediatric Sarcoma Service at the Children's Hospital at Montefiore and an Associate Professor of Pediatrics at the Albert Einstein College of Medicine.Dr. Chou earned his Bachelor of Arts in Biology in 1994 at the University of Pennsylvania. In 1998, he received his Doctor of Medicine at Cornell University Medical College in New York City. Following this, he completed an internship and residency in Pediatrics at New York-Presbyterian Hospital/Weill Cornell Medical Center in New York City.

Biography: Dr. Laura S. Munoz Arcos is an Assistant Professor of Medicine in the Division of Hematology and Medical Oncology at Weill Cornell Medicine and an Assistant Attending Physician at NewYork-Presbyterian Hospital.Dr. Munoz Arcos earned her medical degree from Universidad del Valle in Colombia, her home country. She then completed an internal medicine residency at Montefiore Medical Center/Albert Einstein College of Medicine in the Bronx, NY, followed by a Hematology and Oncology fellowship at Weill Cornell Medicine/NewYork-Presbyterian Hospital, where she served as Chief Fellow in her final year. During her fellowship, Dr. Munoz Arcos gained extensive clinical experience in treating all types of breast cancer while conducting translational research on liquid biopsy in breast cancer at Dr. Massimo Cristofanilli's laboratory. Her research focuses on identifying predictors of response to therapy in hormone receptor-sensitive metastatic breast cancer. In recognition of her work, she received the 2023 Conquer Cancer American Society of Clinical Oncology (ASCO) Young Investigator Award, a prestigious honor granted to only 100 recipients annually. Following the completion of her fellowship, Dr. Munoz Arcos joined the Division of Hematology and Medical Oncology as a faculty member, where she is focused on the treatment of breast cancer.

Biography: Dr. Bobak Parang completed his undergraduate studies at the University of Pennsylvania, where he majored in Biology. He subsequently earned his MD and PhD from Vanderbilt University School of Medicine. He then joined the Weill Cornell Medicine Physician Scientist Training Program where he completed his internal medicine residency and hematology / medical oncology fellowship. During his last year of fellowship, Dr. Parang served as Chief Fellow. As a member of the Weill Cornell Medicine faculty, Dr. Parang is a physician-scientist whose clinical and research interests are focused on lung cancer drug resistance and metastases.

Biography: Dr. Eileen Scigliano, MD is a Hematology Specialist who practices in New York, NY. She is 70 years old and has been practicing for 44 years. Dr. Eileen Scigliano, MD is affiliated with Mount Sinai Hospital.

Biography: Dr. Vaibhav Patel, MD is a Hematology Specialist who practices in New York, NY. He is 38 years old. Dr. Vaibhav Patel, MD is affiliated with Mount Sinai Queens, Mount Sinai Brooklyn and Mount Sinai Hospital.

Biography: Dr. Dominder Kaur received her medical degree from Maharashtra University of Health Sciences, Nashik in India and completed her pediatric residency at Northwell Health Staten Island University Hospital in New York. She trained in pediatric hematology-oncology at the Mayo Clinic in Minnesota while also receiving a Masters in Clinical and Translational Science from the Mayo School of Graduate Medical Education. She received further specialized training as the Joan Wallick Pediatric Hemostasis Thrombosis fellow at the Nationwide Children's Hospital. She joined as faculty at Columbia University/Columbia Presbyterian Medical Center in December 2018 as an Assistant Professor in Pediatrics. Dr. Kaur was the recipient of the Thrombosis & Hemostasis Societies of North America (THSNA) 2018 Young Investigator Award. Her research focus so far has been on bleeding and thrombotic complications stem cell transplant recipients. She is currently working towards improving screening methodology and approaches to bleeding disorder evaluation in children. She is passionate about improving hematological services for young adults, especially young women with possible bleeding disorders. In collaboration with Adolescent Medicine team, Dr. Kaur staffs the Girls & Young-women's Bleeding Issues Clinic (GYBiC). This clinic is one of only two such centers in New York metropolitan area and offers hematological and adolescent medicine specialty consultations and evaluations in one comprehensive visit. The Girls & Young-women's Bleeding Issues Clinic specializes in the diagnosis and treatment of bleeding (like heavy periods/menorrhagia) and clotting disorders (thrombophilia) and accompanying health issues in young women of reproductive age.

Biography: Dr. Sheera Minkowitz, MD is a Radiation Oncology Specialist who practices in Brooklyn, NY. She is 39 years old and has been practicing for 13 years. Dr. Sheera Minkowitz, MD is affiliated with Newyork-Presbyterian.

Biography: Dr. Uqba Khan is an Assistant Professor of Clinical Medicine within the faculty of Weill Cornell Medical College in the Division of Hematology and Medical Oncology. Dr. Khan is also an Attending Physician at NewYork-Presbyterian Brooklyn Methodist Hospital.Dr. Khan received his medical degree from Allama Iqbal Medical College, Pakistan in 2008. He underwent his internal medicine training at St. Agnes Hospital in Baltimore and later completed his hematology/oncology fellowship at St. John Hospital and Medical Center in Detroit, where he also served as chief fellow. Dr. Khan has a special interest in treatment of gastrointestinal (GI) malignancies and clinical research. He joined Weill Cornell Medicine in 2018 to complete an additional year of training in management of gastrointestinal malignancies. He also worked as an instructor at Weill Cornell Medical College between 2018 and 2019. In June of 2019, Dr. Khan was promoted to Assistant Professor of Clinical Medicine within the faculty of Weill Cornell Medical College in the Division of Hematology and Medical Oncology.Dr. Khan has been involved in a number of clinical and translational research studies. His research focuses on optimizing the effectiveness of immunotherapy in solid malignancies. He has published a number of research articles and is actively involved as an investigator in several clinical trials. He has presented his research findingsat several professional conferences and meetings.Dr. Khan is a member of several national and international professional societies, including the American Society of Clinical Oncology (ASCO), the Society of Immunotherapy in Cancer (SITC), the European Society of Medical Oncology (ESMO) and the American Association for Cancer Research (AACR).

Biography: Monica Bhatia, MD specializes in the care of children with noncancerous blood disorders who may benefit from bone marrow transplantation, especially sickle cell anemia. She and her colleagues are working to reduce the toxicity (side effects) and complications of this treatment without compromising its effectiveness, and to make it available to more patients. The field of pediatric hematology brings with it many intellectual challenges, and bone marrow transplantation in particular is especially dynamic. Dr. Bhatia has the opportunity to provide care for the sickest children, potentially curing their disease. She builds strong relationships with her patients and their families that last for years. It is inspiring for her to see young patients grow up to lead healthy, productive lives. NewYork-Presbyterian/Morgan Stanley Children's Hospital has a robust program for bone marrow transplantation for sickle cell anemia - the only cure for this disease. Dr. Bhatia and her team have witnessed remarkable results among children who are cured with bone marrow transplantation and spared from the potentially life-threatening complications of sickle cell disease. Yet despite the advances made, only 15 percent of patients with sickle cell disease have a matched sibling bone marrow donor. Therefore, Dr. Bhatia and her team conduct research to evaluate a procedure called "CD34-selected stem cell transplantation" to remove T-cells from donor bone marrow for patients without a matched sibling donor. This approach reduces the risk of graft-versus-host disease (GVHD), a potential complication of bone marrow transplantation in which T-cells from the donor attack the tissue of the recipient. This approach to harnessing stem cells could potentially make bone marrow transplantation a safer, effective option for many patients who are seeking a cure for sickle cell disease. Dr. Bhatia and her colleagues are currently assessing reduced-intensity transplantation, which uses lower doses of chemotherapy to decrease the risk of side effects and long-term complications without lowering the effectiveness of treatment. She is also interested in looking for ways to further improve the quality of life of patients who have had a bone marrow transplant in addition to fertility preservation.

Biography: Dr. Hua-Jay "Jeff" Cherng is an assistant professor of medicine in the lymphoma program in the Division of Hematology and Oncology. He earned his medical degree from Case Western Reserve University and completed internal medicine residency at the Hospital of the University of Pennsylvania. He subsequently trained at MD Anderson Cancer Center for his hematology and oncology fellowship. He is board certified in Internal Medicine, Hematology and Medical Oncology. Dr. Cherng is a clinical investigator who researches non-invasive response assessment tools such as biomarkers and imaging to predict outcomes of lymphoma patients. His focus is on circulating tumor DNA (ctDNA), fragments of genetic material shed by lymphomas that can be sequenced and tracked to measure molecular response and minimal residual disease. His work on ctDNA and PET scans in lymphoma has led to publications in high-impact journals including Blood, Blood Advances, American Journal of Hematology, and British Journal of Haematology. He has earned abstract merit awards from the American Society of Hematology, American Society of Clinical Oncology, and Pan Pacific Lymphoma Conference. His accomplishments during fellowship earned him a Waun Ki Hong Award for Achievement in Clinical Investigation. His research on ctDNA in patients with relapsed lymphoma receiving chimeric antigen receptor T-cell therapy is funded by a Conquer Cancer Young Investigator Award grant. He is a member of Southwestern Oncology Group Lymphoma Working Group and Committee. He was selected to participate in the Academy of Next Wave of Investigators for non-Hodgkin's lymphoma and the American Society of Hematology Clinical Research Training Institute, competitive programs aimed at supporting academic and career development for promising clinical researchers. Dr. Cherng's goal is to design clinical trials with treatment guided by ctDNA; this would allow for treatment de-escalation in good responders to minimize toxicity and escalation in poor responders to maximize chance for durable remissions. Dr. Cherng sees patients with all types of lymphoma with an emphasis on aggressive non-Hodgkin B-cell lymphomas. He treats patients with standard-of-care treatments as well as on clinical trial protocols.

Biography: Monica Kasbekar, MD, PhD is an Assistant Professor of Medicine at the Columbia Vagelos College of Physicians and Surgeons in the division of Hematology/Oncology and a member of the Herbert Irving Comprehensive Cancer Center. Dr. Kasbekar's clinical practice focuses on the treatment of hematologic malignancies, including acute and chronic leukemias, myeloproliferative neoplasms, and myelodysplastic syndrome. Her research aims to understand how aging and inflammation contribute to the development of blood cancers. Dr. Kasbekar received her MD from Washington University in St. Louis School of Medicine, and her PhD in Chemistry from the University of Cambridge as a National Institutes of Health-Oxford-Cambridge Scholar. She completed her Internal Medicine residency training at Massachusetts General Hospital and her Medical Oncology fellowship at Columbia University Irving Medical Center, where she served as Chief Fellow. Dr. Kasbekar is the recipient of multiple national and international awards including the EvansMDS Young Investigator Award, the American Society of Hematology Research Training Award for Fellows, the NCATS Director's Award for Scientific/Medical Achievement, and the NIH Fellows Award for Research Excellence.

Biography: Dr. Chen is an Assistant Professor of Medicine and medical oncologist specializing in the treatment of thoracic cancers including non-small cell lung cancer, small cell lung cancer, and mesothelioma. She received her bachelor's degree in molecular biology from Princeton University and completed her medical degree at the University of Pennsylvania, where she was inducted into the Alpha Omega Alpha Honor Society. She completed both her internal medicine residency and medical oncology fellowship at Columbia University, where she served as Chief Fellow. In addition to her clinical responsibilities, Dr. Chen has an interest in identifying novel therapies through clinical trials for patients with lung cancer and other tumor types. She received the Journal of Clinical Oncology Young Investigator Award from the American Society of Clinical Oncology in recognition of her work. Above all, Dr. Chen values her relationships with patients and their families and is dedicated to providing compassionate care that is tailored to each patient. She is proud to be part of a multidisciplinary team that works tirelessly to support patients and improve their survival and well-being.

Biography: Mariam El-Ashmawy, MD PhD is a medical oncologist andtranslational scientist with specialization in the treatment of advanced skincancer and ocular melanoma. Her research investigates the complex geneticlandscape of cancer in order to develop new therapies. In the laboratory, her work has been dedicated to understanding the complex genomic landscape of cancer and developing novel targeted therapeutic strategies. Her ongoing projects include testing novel RAS pathway inhibitors in preclinical models of gastric and esophageal cancer as well as a first-in-human clinical trials for patients with NRAS mutant melanoma.

Biography: Linda Wu, MD is an Assistant Professor of Medicine at Columbia University Irving Medical Center. Dr. Wu earned her MD degree from Weill Cornell Medical College and completed residency training in Internal Medicine at NewYork-Presbyterian Hospital/Weill Cornell Medical Center. She then completed fellowship training in Hematology and Medical Oncology at the Icahn School of Medicine at Mount Sinai. As a medical oncologist, she specializes in the treatment of gastrointestinal malignancies, with particular focus on pancreatic and hepatobiliary cancers. Dr. Wu is actively involved in research to improve treatments for cancer. She is involved in developing and leading clinical trials, including multicenter investigator-initiated trials, to investigate novel therapeutic strategies for pancreatic and biliary cancers as well as other gastrointestinal malignancies. Her research interests also include discovering biomarkers predictive of response and resistance to therapy and understanding the tumor microenvironment to improve the effectiveness of immunotherapy for gastrointestinal malignancies, and she has published multiple articles in these areas. Dr. Wu works closely as part of a multidisciplinary team to deliver compassionate care at the highest levels, utilizing a personalized approach to offer cutting-edge therapies.

Biography: James H. Garvin, MD, PhD, is a board-certified pediatric hematologist-oncologist who specializes in the care of children and adolescents with brain tumors. He is Principal Investigator at CUMC for the Head Start Program of radiation-sparing intensive chemotherapy for infants and young children with brain tumors. He was principal investigator for a Children's Oncolgy Group protocol for childhood ependymoma. He also offers novel therapies for recurrent brain tumors through our program's membership in Developmental Therapeutics Program of the COG. In addition, Dr. Garvin started the pediatric bone marrow transplant program, and continues as a member of the BMT group. He has particular interest in autologous transplant for brain tumors and allogeneic transplant for metabolic disorders and bone marrow failure syndromes, as well as supportive care for BMT patients. Dr. Garvin became interested in pediatric hematology/oncology through research during medical school in the laboratory of a pediatric hematologist. He is a member of numerous professional societies in the field.

Care Philosophy: Augusta University Health is a world class health care network offering the most comprehensive care in the region where your health is our priority As leaders in patient and family centered care our physicians partner with our patients their famil

Biography: Dr. Justine Kahn is a Pediatric Oncologist and a clinical investigator specializing in survival outcomes, cancer care delivery, and health equity in children and adolescent/young adults (AYA) with Hodgkin lymphoma, non-Hodgkin lymphoma, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Dr. Kahn received her MD from the Icahn School of Medicine at Mount Sinai in New York and completed her Pediatric Residency at Mount Sinai Kravis Children's Hospital in New York. Dr. Kahn completed her Clinical Fellowship in Pediatric Hematology/Oncology at Columbia University Medical Center. While in residency, Dr. Kahn was elected to Alpha Omega Alpha, the national medical honor society which recognizes high educational achievement. During her fellowship, Dr. Kahn served as a Postdoctoral Research Fellow in Cancer-Related Population Sciences supported by the National Cancer Institute for her work in cancer care delivery, health equity, and health outcomes research. Upon graduation from fellowship, Dr. Kahn joined the Pediatric Hematology/Oncology Division at Columbia University Medical Center as an Oncology Instructor and Attending Physician in 2016. She is currently involved in patient care, clinical trials research, and health outcomes research. In June of 2018, Dr. Kahn obtained a Master of Science in Patient Oriented Research at the Columbia Mailman School of Public Health. In July of 2018 she became an Assistant Professor of Pediatrics in the Division of Pediatric Hematology/Oncology/Stem Cell Transplantation. Dr. Kahn is actively conducting research through studies developed in the Dana-Farber Cancer Institute (DFCI) ALL Consortium, the Children's Oncology Group (COG), and at Columbia University. Columbia boasts a strong commitment to health disparities research in one of the most diverse patient populations in the United States. Dr. Kahn has chosen to focus her research efforts on underserved populations because studies suggest that poor access-to-care, low health literacy, and financial stress can all negatively impact survival in children and AYAs with cancer. Dr. Kahn is supported in part by the Lymphoma Research Foundation and recently received an institutional Career Development Award for her ongoing work on survival disparities in children and AYAs with Hodgkin lymphoma. She serves as CUMC site Principal Investigator for the DFCI ALL Consortium.

Biography: Manuela Orjuela-Grimm is a molecular epidemiologist and pediatric oncologist whose research focuses on vulnerability (including social) to environmental exposures, gene-nutrient/ environment interactions during windows of susceptibility such as pregnancy, early childhood, adolescence and the development of later genetic and epigenetic changes contributing to poorer health outcomes in childhood and adolescence. She leads EpiRbMx, a long-standing case control/ case series study examining exposure to methyl donors, folate pathway metabolism and risk for retinoblastoma in collaboration with a multidisciplinary team of investigators including the Hospital Infantil de Mexico, the Hospital de Pediatria at the Instituto Mexicano de Seguro Social (IMSS), the Instituto Nacional de Salud Publica (INSP), and the University of Toronto. In collaboration with INSP researchers, Dr. Orjuela is involved in multiple studies examining the intersection between food security, folate-related dietary intake, dietary diversity and environmental exposures in central Mexico, and in immigrants in New York. Interests: social contributors to dietary exposures, gene-nutrient interactions; one carbon donor metabolism; methylation; nutrient and environmental exposures during early life and later genetic and epigenetic effects; dietary assessment in Mexico, in populations on the move in Latin America; effects of acculturation and early life migration on nutrient/ environmental exposures in US Latinos.

Biography: Dr. Stergios Zacharoulis, MD is a Radiation Oncology Specialist who practices in New York, NY. He is 55 years old and has been practicing for 30 years. Dr. Stergios Zacharoulis, MD is affiliated with Newyork-Presbyterian/Columbia University Medical Center and Newyork-Presbyterian/Morgan Stanley Children's Hospital.

Biography: Originally from Columbus, OH, SunilIyercompleted his undergraduate studies at Washington University in St. Louis. He then completed his medical education and training at the University of Miami, where he served as chief hematology/oncology fellow. He has a strong interest in leukemia, particularly in the genomics and treatment of acute lymphoblastic leukemia.

Biography: Dr. Tamna Wangjam, MD is a Hematology Specialist who practices in New York, NY. She is 39 years old and has been practicing for 16 years. Dr. Tamna Wangjam, MD is affiliated with Newyork-Presbyterian/Columbia University Medical Center.

Care Philosophy: We are committed to delivering the best care and an exceptional patient experience. We are devoted to providing services that are patient-centered and compassionate, and care for you as a person.

Biography: Dr. Sathe completed her Residency in Internal Medicine at NYP/Weill Cornell and is a graduate of Rutgers-New Jersey Medical School. She also holds a JD from Columbia Law School. Her research focuses on improving cancer care delivery and reducing disparities in treatment and outcomes.

Biography: Dr. Andrew H. Lipsky is an Assistant Professor of Medicine at the Columbia University Medical Center. He specializes in caring for adult patients with hematologic malignancies, including chronic lymphocytic leukemia (CLL) and lymphoma.Dr. Lipsky's research focuses on cancer genomics and new treatments for CLL. He has a special interest in using the latest bioinformatics techniques to study how cancer cells change and adapt during treatment. Utilizing these genomic insights, he hopes to better inform clinical trials and hasten the development of innovative therapies for patients with hematologic malignancies.Dr. Lipsky earned his medical degree from Rutgers - Robert Wood Johnson Medical School. He completed internship and residency in internal medicine at Montefiore - Albert Einstein College of Medicine. He completed fellowship training in Hematology and Medical Oncology at New York Presbyterian Hospital Weill Cornell Medical College, with an additional sub-fellowship in the clinical care of CLL and lymphoma. He also completed a postdoctoral research fellowship in lymphoma genomics and bioinformatics as part of the Molecular and Translation Oncology Research (MTOR) training program.

Biography: Dr. Henick is a medical oncologist specializing in the care of patients with malignancies of the aerodigestive tract.As the Associate Director of Experimental Therapeutics and Director of Translational Research in Aerodigestive Cancers in Medical Oncology, Dr. Henick's clinical care and research are aligned to improve the effectiveness of, and limit toxicity from, emerging cancer treatments. These effortsentail clinical trials that Dr. Henick has written and leads to study novel therapeutic approaches and to reduce steroid dependence among patients experiencing adverse events fromimmunotherapy.